Research trends in olanzapine in treating schizophrenia from 2010 to 2026

Background: Schizophrenia is a severe chronic mental disorder, and olanzapine is widely used in its treatment. However, the expanding and heterogeneous literature on olanzapine in schizophrenia has not been comprehensively characterized from a bibliometric perspective. Therefore, this study aimed to systematically characterize the research landscape, hotspots, emerging frontiers, and knowledge evolution of olanzapine in the treatment of schizophrenia from 2010 to 2026. Methods: Literature on olanzapine for the treatment of schizophrenia published between January 1, 2010, and March 29, 2026, was retrieved from the Web of Science Core Collection. CiteSpace (version 6.4.R2) and the Bibliometrix R package were used for bibliometric and visual analyses. Multiple bibliometric characteristics were analyzed, including publication trends, national and institutional distributions, core authors, journal distributions, co-citation of references, co-occurrence, clustering, keyword burst detection, and disciplinary biclustering. Results: A total of 3943 valid publications were included. Annual publication volume generally increased over the study period, despite periodic minor fluctuations. The United States, China, and the United Kingdom accounted for the largest shares of publication output. From a bibliometric perspective, University College London stood out as a hub node within the collaboration network. Correll CU and Leucht S represented highly productive contributors. Schizophrenia Research was the most productive journal in terms of publication output. Keyword analysis indicated that the research focus gradually shifted from evaluation of drug efficacy and dosage-form development to metabolic risk management, personalized treatment, and real-world clinical research. Recent research primarily focused on population-based cohort studies, comparative evaluations of treatment efficacy, clinical practice guidelines, and treatment-related risk assessment. Conclusion: Research on olanzapine for the treatment of schizophrenia is ongoing. Current studies have shifted from efficacy verification to safety monitoring, with growing emphasis on population-based individualized dose adjustment, metabolic risk management, and large-sample comparative clinical studies for clinical guideline optimization.